Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs MB 101 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 28 Dec 2016 Single patient data prompted the expansion of this study to evaluate intraventricular administration in a larger cohort of patients, as per a Fortess Biotech media release.
- 28 Dec 2016 A patient case study results published in a Fortess Biotech media release.
- 28 Dec 2016 A patient case study details will be published in the December 29 edition of the New England Journal of Medicine, as per a Fortess Biotech media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History